Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Adma Biologics (NQ: ADMA )

19.37 +3.06 (+18.76%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 11,737,930
Open 18.29
Bid (Size) 19.10 (1)
Ask (Size) 19.38 (19)
Prev. Close 16.31
Today's Range 18.24 - 20.18
52wk Range 3.455 - 21.13
Shares Outstanding 196,357,149
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
What You Missed On Wall Street This Past Friday
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 
Via Talk Markets
Amazon Posts Upbeat Results, Joins Cardinal Health, Waters, Atlassian, Charter Communications, MasTec And Other Big Stocks Moving Higher On Friday
Via Benzinga

Performance

YTD
+325.71%
+325.71%
1 Month
-1.02%
-1.02%
3 Month
+71.42%
+71.42%
6 Month
+180.32%
+180.32%
1 Year
+430.68%
+430.68%

More News

Read More
ADMA Biologics, A Top 1% Stock, Skyrockets After Settling Its Accounting Debacle
Via Investor's Business Daily
ADMA Biologics to Report Third Quarter 2024 Financial Results on November 7, 2024
From ADMA Biologics, Inc.
Via GlobeNewswire
(ADMA) - Analyzing ADMA Biologics's Short Interest
Via Benzinga
ADMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into ADMA Biologics Inc and Encourages Investors to Contact the Firm
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
ADMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into ADMA Biologics Inc and Encourages Investors to Contact the Firm
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Bragar Eagel & Squire, P.C. Is Investigating ADMA Biologics, Napco, and L&W and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Key Takeaways From ADMA Biologics Analyst Ratings
Via Benzinga
This Is What Whales Are Betting On ADMA Biologics
Via Benzinga
ADMA BIOLOGICS ALERT: Bragar Eagel & Squire, P.C. is Investigating ADMA Biologics, Inc. on Behalf of ADMA Biologics Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Amphastar Casts Wide Net, Hauls In Profits, Gets Rating Upgrade
Via Investor's Business Daily
Alkermes Stock Jumps Nearly 30% In 3 Months Amid Hefty Profits
Via Investor's Business Daily
CVS Has 'Real Value,' Jim Cramer Says: Micron Had An 'Amazing' Quarter
Via Benzinga
IBD 50's Top Stock, ADMA Biologics, Crashes After Auditor Unexpectedly Resigns
Via Investor's Business Daily
Exploring high growth characteristics of ADMA BIOLOGICS INC (NASDAQ:ADMA).
Via Chartmill
Looking for growth without the hefty price tag? Consider NASDAQ:ADMA.
Via Chartmill
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
In-Depth Examination Of 4 Analyst Recommendations For ADMA Biologics
Via Benzinga
ADMA Biologics Set to Join S&P SmallCap 600 Index
From ADMA Biologics, Inc.
Via GlobeNewswire
ADMA Biologics to Participate in the 2024 Cantor Global Healthcare Conference
From ADMA Biologics, Inc.
Via GlobeNewswire
What's Going On With ADMA Biologics Stock Monday?
Via Benzinga
Topics Stocks
Exposures US Equities
Terns Pharmaceuticals, Boeing, Tesla And Other Big Stocks Moving Higher On Monday
Via Benzinga
Keros Therapeutics Stock Meets 80-Plus RS Rating Benchmark
Via Investor's Business Daily
'This Is A Very Speculative Situation,' Jim Cramer On ADMA Biologics
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.